Current Alzheimer Research

Current Alzheimer Research

Editor-in-Chief

ISSN (Print): 1567-2050
ISSN (Online): 1875-5828

Back Subscribe
Translate in Chinese
Research Article

Effective Analysis of Alzheimer's Disease and Mechanisms of Methyl-4- Hydroxybenzoate using Network Toxicology, Molecular Docking, and Machine Learning Strategies

Author(s): Jianren Wen, Jingxuan Hu, Xue Yang, Feifei Luo and Guohui Zou*

Volume 22, Issue 6, 2025

Published on: 15 July, 2025

Page: [456 - 475] Pages: 20

DOI: 10.2174/0115672050399031250623062112

Price: $65

Become a Editorial Board Member
Become a Reviewer
Become a Editor
Become a Section Editor

Abstract

Introduction: Nowadays, the large increase in environmental pollutants has led to the occurrence and development of an increasing number of diseases. Studies have shown that exposure to environmental pollutants, such as methyl-4-hydroxybenzoate (MEP) may lead to Alzheimer's disease (AD). Therefore, the purpose of this study was to elucidate the complex effects and potential molecular mechanisms of environmental pollutants MEP on AD.

Methods: Through exhaustive exploration of databases, such as ChEMBL, STITCH, SwissTarget- Prediction, and Gene Expression Omnibus DataSets (GEO DataSets), we have identified a comprehensive list of 46 potential targets closely related to MEP and AD. After rigorous screening using the STRING platform and Cytoscape software, we narrowed the list to nine candidate targets and ultimately identified six hub targets using three proven machine learning methods (LASSO, RF, and SVM): CREBBP, BCL6, CXCR4, GRIN1, GOT2, and ITGA5. The “clusterProfiler” R package was used to conduct GO and KEGG enrichment analysis. At the same time, we also constructed disease prediction models for core genes. At last, six hub targets were executed molecular docking.

Results: We derived 46 key target genes related to MEP and AD and conducted gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. MEP might play a role in AD by affecting the pathways of neuroactive ligand-receptor interaction. Nine genes were screened as pivotal targets, followed by machine learning methods to identify six hub targets. Molecular docking analysis showed a good binding ability between MEP and CREBBP, BCL6, CXCR4, GRIN1, GOT2 and ITGA5. In addition, changes in the immune microenvironment revealed a significant impact of immune status on AD.

Discussions: This study revealed that MEP may induce AD through multiple mechanisms, such as oxidative stress, neurotoxicity, and immune regulation, and identified six core targets (CREBBP, BCL6, etc.) and found that they are related to changes in the immune microenvironment, such as T cells and B cells, providing new molecular targets for AD intervention.

Conclusion: Overall, CREBBP, BCL6, CXCR4, GRIN1, GOT2, and ITGA5 have been identified as the crucial targets correlating with AD. Our findings provide a theoretical framework for understanding the complex molecular mechanisms underlying the effects of MEP on AD and provide insights for the development of prevention and treatment of AD caused by exposure to MEP.

Keywords: Methyl-4-hydroxybenzoate, environmental pollutants, Alzheimer's disease, network toxicology, molecular docking, machine learning.

« Previous
[1]
Tiwari S, Atluri V, Kaushik A, Yndart A, Nair M. Alzheimer’s disease: Pathogenesis, diagnostics, and therapeutics. Int J Nanomedicine 2019; 14: 5541-54.
[http://dx.doi.org/10.2147/IJN.S200490] [PMID: 31410002]
[2]
Lane CA, Hardy J, Schott JM. Alzheimer’s disease. Eur J Neurol 2018; 25(1): 59-70.
[http://dx.doi.org/10.1111/ene.13439] [PMID: 28872215]
[3]
Tahami MAA, Byrnes MJ, White LA, Zhang Q. Alzheimer’s disease: Epidemiology and clinical progression. Neurol Ther 2022; 11(2): 553-69.
[http://dx.doi.org/10.1007/s40120-022-00338-8] [PMID: 35286590]
[4]
Scheltens P, De Strooper B, Kivipelto M, et al. Alzheimer’s disease. Lancet 2021; 397(10284): 1577-90.
[http://dx.doi.org/10.1016/S0140-6736(20)32205-4] [PMID: 33667416]
[5]
Sheppard O, Coleman M. Alzheimer’s disease: Etiology, neuropathology and pathogenesis. In: Huang X, Ed. Alzheimer’s Disease: Drug Discovery. Brisbane (AU): Exon Publications 2020.
[6]
Mir RH, Sawhney G, Pottoo FH, et al. Role of environmental pollutants in Alzheimer’s disease: A review. Environ Sci Pollut Res Int 2020; 27(36): 44724-42.
[http://dx.doi.org/10.1007/s11356-020-09964-x] [PMID: 32715424]
[7]
Ma YH, Chen HS, Liu C, et al. Association of long-term exposure to ambient air pollution with cognitive decline and Alzheimer’s disease–related amyloidosis. Biol Psychiatry 2023; 93(9): 780-9.
[http://dx.doi.org/10.1016/j.biopsych.2022.05.017] [PMID: 35953319]
[8]
Vasefi M, Ghaboolian-Zare E, Abedelwahab H, Osu A. Environmental toxins and Alzheimer’s disease progression. Neurochem Int 2020; 141: 104852.
[http://dx.doi.org/10.1016/j.neuint.2020.104852] [PMID: 33010393]
[9]
Manivannan B, Yegambaram M, Supowit S, Beach TG, Halden RU. Assessment of persistent, bioaccumulative and toxic organic environmental pollutants in liver and adipose tissue of Alzheimer’s disease patients and age-matched controls. Curr Alzheimer Res 2019; 16(11): 1039-49.
[http://dx.doi.org/10.2174/1567205016666191010114744] [PMID: 31660829]
[10]
Dhapola R, Sharma P, Kumari S, Bhatti JS, HariKrishnaReddy D. Environmental toxins and Alzheimer’s disease: A comprehensive analysis of pathogenic mechanisms and therapeutic modulation. Mol Neurobiol 2024; 61(6): 3657-77.
[http://dx.doi.org/10.1007/s12035-023-03805-x] [PMID: 38006469]
[11]
Olloquequi J, Díaz-Peña R, Verdaguer E, Ettcheto M, Auladell C, Camins A. From inhalation to neurodegeneration: Air pollution as a modifiable risk factor for Alzheimer’s disease. Int J Mol Sci 2024; 25(13): 6928.
[http://dx.doi.org/10.3390/ijms25136928] [PMID: 39000036]
[12]
Kuntić M, Hahad O, Münzel T, Daiber A. Crosstalk between oxidative stress and inflammation caused by noise and air pollution—implications for neurodegenerative diseases. Antioxidants 2024; 13(3): 266.
[http://dx.doi.org/10.3390/antiox13030266] [PMID: 38539800]
[13]
Song H, Zhou H, Yang S, He C. Combining mendelian randomization analysis and network toxicology strategy to identify causality and underlying mechanisms of environmental pollutants with glioblastoma: A study of Methyl-4-hydroxybenzoate. Ecotoxicol Environ Saf 2024; 287: 117311.
[http://dx.doi.org/10.1016/j.ecoenv.2024.117311] [PMID: 39536568]
[14]
Sharfalddin A, Davaasuren B, Emwas AH, Jaremko M, Jaremko Ł, Hussien M. Single crystal, Hirshfeld surface and theoretical analysis of methyl 4-hydroxybenzoate, a common cosmetic, drug and food preservative—Experiment versus theory. PLoS One 2020; 15(10): 0239200.
[http://dx.doi.org/10.1371/journal.pone.0239200] [PMID: 33021975]
[15]
Xiang J, Lv BR, Shi Y, Chen W, Zhang J. Environmental pollution of paraben needs attention: A study of methylparaben and butylparaben co-exposure trigger neurobehavioral toxicity in zebrafish. Environ Pollut 2024; 356: 124370.
[http://dx.doi.org/10.1016/j.envpol.2024.124370] [PMID: 38876377]
[16]
Seymore TN, Rivera-Núñez Z, Stapleton PA, Adibi JJ, Barrett ES. Phthalate exposures and placental health in animal models and humans: A systematic review. Toxicol Sci 2022; 188(2): 153-79.
[http://dx.doi.org/10.1093/toxsci/kfac060] [PMID: 35686923]
[17]
Comeche A, Martín-Villamil M, Picó Y, Varó I. Effect of methylparaben in Artemia franciscana. Comp Biochem Physiol C Toxicol Pharmacol 2017; 199: 98-105.
[http://dx.doi.org/10.1016/j.cbpc.2017.04.004] [PMID: 28428009]
[18]
da Silveira FFCL, Porto VA, de Sousa BLC, et al. Bioaccumulation and ecotoxicity of parabens in aquatic organisms: Current status and trends. Environ Pollut 2024; 363(Pt 2): 125213.
[http://dx.doi.org/10.1016/j.envpol.2024.125213] [PMID: 39477001]
[19]
Hu C, Bai Y, Li J, Sun B, Chen L. Endocrine disruption and reproductive impairment of methylparaben in adult zebrafish. Food Chem Toxicol 2023; 171: 113545.
[http://dx.doi.org/10.1016/j.fct.2022.113545] [PMID: 36470324]
[20]
Nowak K, Jabłońska E, Garley M, Radziwon P, Ratajczak-Wrona W. Methylparaben-induced regulation of estrogenic signaling in human neutrophils. Mol Cell Endocrinol 2021; 538: 111470.
[http://dx.doi.org/10.1016/j.mce.2021.111470] [PMID: 34606965]
[21]
Mushtaq G, Greig N, Khan J, Kamal M. Status of acetylcholinesterase and butyrylcholinesterase in Alzheimer’s disease and type 2 diabetes mellitus. CNS Neurol Disord Drug Targets 2014; 13(8): 1432-9.
[http://dx.doi.org/10.2174/1871527313666141023141545] [PMID: 25345511]
[22]
McGleenon BM, Dynan KB, Passmore AP. Acetylcholinesterase inhibitors in Alzheimer’s disease. Br J Clin Pharmacol 1999; 48(4): 471-80.
[http://dx.doi.org/10.1046/j.1365-2125.1999.00026.x] [PMID: 10583015]
[23]
Aloui M, El fadili M, Mujwar S, et al. In silico design of novel pyridazine derivatives as balanced multifunctional agents against Alzheimer’s disease. Sci Rep 2025; 15(1): 15910.
[http://dx.doi.org/10.1038/s41598-025-98182-x] [PMID: 40335607]
[24]
Liu S, Wang Z, Zhu R, Wang F, Cheng Y, Liu Y. Three differential expression analysis methods for RNA sequencing: Limma, EdgeR, DESeq2. J Vis Exp 2021; 175: 2021-09-18.
[http://dx.doi.org/10.3791/62528]
[25]
Wu T, Hu E, Xu S, et al. ClusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innovation 2021; 2(3): 100141.
[http://dx.doi.org/10.1016/j.xinn.2021.100141] [PMID: 34557778]
[26]
Tian L, Wu W, Yu T. Graph random forest: A graph embedded algorithm for identifying highly connected important features. Biomolecules 2023; 13(7): 1153.
[http://dx.doi.org/10.3390/biom13071153] [PMID: 37509188]
[27]
Xu L, Shi M, Qin G, Lin X, Huang B. Environmental pollutant Di-(2-ethylhexyl) phthalate induces asthenozoospermia: New insights from network toxicology. Molec Divers 2025; 29(3): 2179-92.
[http://dx.doi.org/10.1007/s11030-024-10976-9]
[28]
Darbre PD, Byford JR, Shaw LE, et al. Oestrogenic activity of benzylparaben. J Appl Toxicol 2003; 23(1): 43-51.
[http://dx.doi.org/10.1002/jat.886] [PMID: 12518336]
[29]
Gindorf M, Storck SE, Ohler A, Scharfenberg F, Becker- Pauly C, Pietrzik CU. Meprin β: A novel regulator of blood–brain barrier integrity. J Cereb Blood Flow Metab 2021; 41(1): 31-44.
[http://dx.doi.org/10.1177/0271678X20905206] [PMID: 32065075]
[30]
Reitz C, Brayne C, Mayeux R. Epidemiology of Alzheimer disease. Nat Rev Neurol 2011; 7(3): 137-52.
[http://dx.doi.org/10.1038/nrneurol.2011.2] [PMID: 21304480]
[31]
Go W, Ishak IH, Zarkasi KZ, Azzam G. Salvianolic acids modulate lifespan and gut microbiota composition in amyloid-β- expressing Drosophila melanogaster. World J Microbiol Biotechnol 2024; 40(11): 358.
[http://dx.doi.org/10.1007/s11274-024-04163-z] [PMID: 39428437]
[32]
Martins FC, Oliveira MM, Gaivão I, A Videira R, Peixoto F. The administration of methyl and butyl parabens interferes with the enzymatic antioxidant system and induces genotoxicity in rat testis: Possible relation to male infertility. Drug Chem Toxicol 2024; 47(3): 322-9.
[http://dx.doi.org/10.1080/01480545.2023.2176512] [PMID: 36756703]
[33]
Sears SMS, Hewett SJ. Influence of glutamate and GABA transport on brain excitatory/inhibitory balance. Exp Biol Med 2021; 246(9): 1069-83.
[http://dx.doi.org/10.1177/1535370221989263] [PMID: 33554649]
[34]
Wang Y, Xia J, Shen M, et al. Effects of BIS-MEP on reversing amyloid plaque deposition and spatial learning and memory impairments in a mouse model of β-amyloid peptide- and ibotenic acid-induced Alzheimer’s disease. Front Aging Neurosci 2019; 11: 3.
[http://dx.doi.org/10.3389/fnagi.2019.00003] [PMID: 30723404]
[35]
Farina M, Aschner M, Rocha JBT. Oxidative stress in MeHg-induced neurotoxicity. Toxicol Appl Pharmacol 2011; 256(3): 405-17.
[http://dx.doi.org/10.1016/j.taap.2011.05.001] [PMID: 21601588]
[36]
Polunas M, Halladay A, Tjalkens RB, Philbert MA, Lowndes H, Reuhl K. Role of oxidative stress and the mitochondrial permeability transition in methylmercury cytotoxicity. Neurotoxicology 2011; 32(5): 526-34.
[http://dx.doi.org/10.1016/j.neuro.2011.07.006] [PMID: 21871920]
[37]
Kandimalla R, Reddy PH. Therapeutics of neurotransmitters in Alzheimer’s disease. J Alzheimers Dis 2017; 57(4): 1049-69.
[http://dx.doi.org/10.3233/JAD-161118] [PMID: 28211810]
[38]
Yang Z, Zou Y, Wang L. Neurotransmitters in prevention and treatment of Alzheimer’s disease. Int J Mol Sci 2023; 24(4): 3841.
[http://dx.doi.org/10.3390/ijms24043841] [PMID: 36835251]
[39]
Wang R, Reddy PH. Role of glutamate and NMDA receptors in Alzheimer’s disease. J Alzheimers Dis 2017; 57(4): 1041-8.
[http://dx.doi.org/10.3233/JAD-160763] [PMID: 27662322]
[40]
Conn KA, Borsom EM, Cope EK. Implications of microbe-derived ɣ-aminobutyric acid (GABA) in gut and brain barrier integrity and GABAergic signaling in Alzheimer’s disease. Gut Microbes 2024; 16(1): 2371950.
[http://dx.doi.org/10.1080/19490976.2024.2371950] [PMID: 39008552]
[41]
Kocahan S, Doğan Z. Mechanisms of Alzheimer’s disease pathogenesis and prevention: The brain, neural pathology, n-methyl-d-aspartate receptors, tau protein and other risk factors. Clin Psychopharmacol Neurosci 2017; 15(1): 1-8.
[http://dx.doi.org/10.9758/cpn.2017.15.1.1] [PMID: 28138104]
[42]
Brodin L, Shupliakov O. Retromer in synaptic function and pathology. Front Synaptic Neurosci 2018; 10: 37.
[http://dx.doi.org/10.3389/fnsyn.2018.00037] [PMID: 30405388]
[43]
Lamas JA, Selyanko AA, Brown DA. Effects of a cognition-enhancer, linopirdine (DuP 996), on M-type potassium currents (IK(M)) and some other voltage- and ligand-gated membrane currents in rat sympathetic neurons. Eur J Neurosci 1997; 9(3): 605-16.
[http://dx.doi.org/10.1111/j.1460-9568.1997.tb01637.x] [PMID: 9104602]
[44]
Hu C, Bai Y, Sun B, Zhou X, Chen L. Exposure to methylparaben at environmentally realistic concentrations significantly impairs neuronal health in adult zebrafish. J Environ Sci 2023; 132: 134-44.
[http://dx.doi.org/10.1016/j.jes.2022.07.012] [PMID: 37336604]
[45]
Li S, Xiao J, Huang C, Sun J. Identification and validation of oxidative stress and immune-related hub genes in Alzheimer’s disease through bioinformatics analysis. Sci Rep 2023; 13(1): 657.
[http://dx.doi.org/10.1038/s41598-023-27977-7] [PMID: 36635346]
[46]
Zhang J, Mohamad FH, Wong JH, et al. The effects of 4-hydroxybenzoic acid identified from bamboo (Dendrocalamus asper) shoots on kv1.4 channel. Malays J Med Sci 2018; 25(1): 101-13.
[http://dx.doi.org/10.21315/mjms2018.25.1.12] [PMID: 29599640]
[47]
Winter AN, Brenner MC, Punessen N, et al. Comparison of the neuroprotective and anti-inflammatory effects of the anthocyanin metabolites, protocatechuic acid and 4-hydroxybenzoic acid. Oxid Med Cell Longev 2017; 2017(1): 6297080.
[http://dx.doi.org/10.1155/2017/6297080] [PMID: 28740571]
[48]
Wang Q, Qiao W, Zhang H, et al. Nomogram established on account of Lasso- Cox regression for predicting recurrence in patients with early-stage hepatocellular carcinoma. Front Immunol 2022; 13: 1019638.
[http://dx.doi.org/10.3389/fimmu.2022.1019638] [PMID: 36505501]
[49]
Dai P, Chang W, Xin Z, Cheng H, Ouyang W, Luo A. Retrospective study on the influencing factors and prediction of hospitalization expenses for chronic renal failure in China based on random forest and LASSO regression. Front Public Health 2021; 9: 678276.
[http://dx.doi.org/10.3389/fpubh.2021.678276] [PMID: 34211956]
[50]
Silva GFS, Fagundes TP, Teixeira BC, Chiavegatto FADP. Machine learning for hypertension prediction: A systematic review. Curr Hypertens Rep 2022; 24(11): 523-33.
[http://dx.doi.org/10.1007/s11906-022-01212-6] [PMID: 35731335]
[51]
Alamro H, Thafar MA, Albaradei S, Gojobori T, Essack M, Gao X. Exploiting machine learning models to identify novel Alzheimer’s disease biomarkers and potential targets. Sci Rep 2023; 13(1): 4979.
[http://dx.doi.org/10.1038/s41598-023-30904-5] [PMID: 36973386]
[52]
Zhao S, Ye B, Chi H, Cheng C, Liu J. Identification of peripheral blood immune infiltration signatures and construction of monocyte-associated signatures in ovarian cancer and Alzheimer’s disease using single-cell sequencing. Heliyon 2023; 9(7): 17454.
[http://dx.doi.org/10.1016/j.heliyon.2023.e17454] [PMID: 37449151]
[53]
Dong Y, Li T, Ma Z, Zhou C, Wang X, Li J. HSPA1A, HSPA2, and HSPA8 are potential molecular biomarkers for prognosis among HSP70 family in Alzheimer’s disease. Dis Markers 2022; 2022: 1-16.
[http://dx.doi.org/10.1155/2022/9480398] [PMID: 36246562]
[54]
Rahman MR, Islam T, Turanli B, et al. Network-based approach to identify molecular signatures and therapeutic agents in Alzheimer’s disease. Comput Biol Chem 2019; 78: 431-9.
[http://dx.doi.org/10.1016/j.compbiolchem.2018.12.011] [PMID: 30606694]
[55]
Bellenie BR, Cheung KMJ, Varela A, et al. Achieving in vivo target depletion through the discovery and optimization of benzimidazolone BCL6 degraders. J Med Chem 2020; 63(8): 4047-68.
[http://dx.doi.org/10.1021/acs.jmedchem.9b02076] [PMID: 32275432]
[56]
Baron BW, Baron RM, Baron JM. The ITM2B (BRI2) gene is a target of BCL6 repression: Implications for lymphomas and neurodegenerative diseases. Biochim Biophys Acta Mol Basis Dis 2015; 1852(5): 742-8.
[http://dx.doi.org/10.1016/j.bbadis.2014.12.018] [PMID: 25557390]
[57]
Baron BW, Pytel P. Expression pattern of the BCL6 and itm2b proteins in normal human brains and in Alzheimer disease. Appl Immunohistochem Mol Morphol 2017; 25(7): 489-96.
[http://dx.doi.org/10.1097/PAI.0000000000000329] [PMID: 26862951]
[58]
Kim K, Wang X, Ragonnaud E, et al. Therapeutic B-cell depletion reverses progression of Alzheimer’s disease. Nat Commun 2021; 12(1): 2185.
[http://dx.doi.org/10.1038/s41467-021-22479-4] [PMID: 33846335]
[59]
Bezzi P, Domercq M, Brambilla L, et al. CXCR4-activated astrocyte glutamate release via TNFα: Amplification by microglia triggers neurotoxicity. Nat Neurosci 2001; 4(7): 702-10.
[http://dx.doi.org/10.1038/89490] [PMID: 11426226]
[60]
Parachikova A, Agadjanyan MG, Cribbs DH, et al. Inflammatory changes parallel the early stages of Alzheimer disease. Neurobiol Aging 2007; 28(12): 1821-33.
[http://dx.doi.org/10.1016/j.neurobiolaging.2006.08.014] [PMID: 17052803]
[61]
Parachikova A, Cotman CW. Reduced CXCL12/CXCR4 results in impaired learning and is downregulated in a mouse model of Alzheimer disease. Neurobiol Dis 2007; 28(2): 143-53.
[http://dx.doi.org/10.1016/j.nbd.2007.07.001] [PMID: 17764962]
[62]
Ragnarsson L, Zhang Z, Das SS, et al. GRIN1 variants associated with neurodevelopmental disorders reveal channel gating pathomechanisms. Epilepsia 2023; 64(12): 3377-88.
[http://dx.doi.org/10.1111/epi.17776] [PMID: 37734923]
[63]
Korinek M, Candelas Serra M, Abdel Rahman FES, et al. Disease-associated variants in GRIN1, GRIN2A and GRIN2B genes: Insights into NMDA receptor structure, function, and pathophysiology. Physiol Res 2024; 73(Suppl. 1): S413-34.
[http://dx.doi.org/10.33549/physiolres.935346] [PMID: 38836461]
[64]
Mitra S, Bp K, C R S, Saikumar NV, Philip P, Narayanan M. Alzheimer’s disease rewires gene coexpression networks coupling different brain regions. NPJ Syst Biol Appl 2024; 10(1): 50.
[http://dx.doi.org/10.1038/s41540-024-00376-y] [PMID: 38724582]
[65]
Han Y, Chen K, Yu H, et al. Maf1 loss regulates spinogenesis and attenuates cognitive impairment in Alzheimer’s disease. Brain 2024; 147(6): 2128-43.
[http://dx.doi.org/10.1093/brain/awae015] [PMID: 38226680]
[66]
Li Y, Li B, Xu Y, et al. GOT2 silencing promotes reprogramming of glutamine metabolism and sensitizes hepatocellular carcinoma to glutaminase inhibitors. Cancer Res 2022; 82(18): 3223-35.
[http://dx.doi.org/10.1158/0008-5472.CAN-22-0042] [PMID: 35895805]
[67]
Kang S, Lee Y, Lee JE. Metabolism-centric overview of the pathogenesis of Alzheimer’s disease. Yonsei Med J 2017; 58(3): 479-88.
[http://dx.doi.org/10.3349/ymj.2017.58.3.479] [PMID: 28332351]
[68]
Ezkurdia A, Ramírez MJ, Solas M. Metabolic syndrome as a risk factor for Alzheimer’s disease: A focus on insulin resistance. Int J Mol Sci 2023; 24(5): 4354.
[http://dx.doi.org/10.3390/ijms24054354] [PMID: 36901787]
[69]
Chen Z, Balachandran YL, Chong WP, Chan KWY. Roles of cytokines in Alzheimer’s disease. Int J Mol Sci 2024; 25(11): 5803.
[http://dx.doi.org/10.3390/ijms25115803] [PMID: 38891990]
[70]
Goel P, Chakrabarti S, Goel K, Bhutani K, Chopra T, Bali S. Neuronal cell death mechanisms in Alzheimer’s disease: An insight. Front Mol Neurosci 2022; 15: 937133.
[http://dx.doi.org/10.3389/fnmol.2022.937133] [PMID: 36090249]
[71]
Gao C, Jiang J, Tan Y, Chen S. Microglia in neurodegenerative diseases: Mechanism and potential therapeutic targets. Signal Transduct Target Ther 2023; 8(1): 359.
[http://dx.doi.org/10.1038/s41392-023-01588-0] [PMID: 37735487]
[72]
Liang C, Yuan Z, Yang S, et al. Mannose promotes β-amyloid pathology by regulating BACE1 glycosylation in Alzheimer’s disease. Adv Sci 2025; 12(9): 2409105.
[http://dx.doi.org/10.1002/advs.202409105] [PMID: 39807036]
[73]
Li S, Zhang N, Liu S, et al. ITGA5 is a novel oncogenic biomarker and correlates with tumor immune microenvironment in gliomas. Front Oncol 2022; 12: 844144.
[http://dx.doi.org/10.3389/fonc.2022.844144] [PMID: 35371978]
[74]
Mahzarnia A, Lutz MW, Badea A. A continuous extension of gene set enrichment analysis using the likelihood ratio test statistics identifies vascular endothelial growth factor as a candidate pathway for Alzheimer’s disease via ITGA5. J Alzheimers Dis 2024; 97(2): 635-48.
[http://dx.doi.org/10.3233/JAD-230934] [PMID: 38160360]
[75]
Burgaletto C, Munafò A, Di Benedetto G, et al. The immune system on the TRAIL of Alzheimer's disease. J Neuroinflamm 2020; 17(1): 298. 2020-10-13
[http://dx.doi.org/10.1186/s12974-020-01968-1]
[76]
Kinney JW, Bemiller SM, Murtishaw AS, Leisgang AM, Salazar AM, Lamb BT. Inflammation as a central mechanism in Alzheimer’s disease. Alzheimers Dement 2018; 4(1): 575-90.
[http://dx.doi.org/10.1016/j.trci.2018.06.014] [PMID: 30406177]
[77]
Linzhu Z, Zhang J, Fan W, Su C, Jin Z. Influence of immune cells and inflammatory factors on Alzheimer’s disease axis: Evidence from mediation Mendelian randomization study. BMC Neurol 2025; 25(1): 49.
[http://dx.doi.org/10.1186/s12883-025-04057-z] [PMID: 39910474]

Rights & Permissions Print Cite